Sexually-transmitted infections: What´s new about the control of chlamydia trachomatis

Autores
Damiani, Maria Elena
Año de publicación
2019
Idioma
inglés
Tipo de recurso
documento de conferencia
Estado
versión publicada
Descripción
Chlamydia trachomatis (Ctr) is the most common bacterial cause of sexually transmitted infections (STIs). The World Health Organization (WHO) estimates that 131 million are infected each year, mainly young people of reproductive age. In women, Ctr causes cervicitis, endometritis, salpingitis, which frequently persist along time leading to serious complications such as pelvic inflammatory disease, spontaneous abortions and tubal infertility. Newborns, when infected in the birth canal, can develop conjunctivitis and pneumonia; whereas men can suffer urethritis, prostatitis, and epididymitis. Ctr is the main cause of preventable blindness or trachoma worldwide. There was an epidemiological alert in Argentina in August 2018 for the appearance of venereal lymphogranuloma. The asymptomatic nature of most of the infections makes diagnosis and treatment difficult. Besides, the lack of a preventive vaccine and the antibiotic resistance increase reveal the need for new tools for the prevention and control of chlamydial infections. Ctr invades cervical epithelial cells through numerous receptors, many of them glycosylated, and survives and multiplies intracellularly in a vesicle called inclusion. We have shown the release of a glycan-binding protein, galectin 1 (Gal1), in cervical tissues under inflammation. This lectin engages glycosylated bacterial proteins, like MOMP (Major Outer Membrane Protein) and OmcB, to glycosylated cervical epithelial cell receptors such as PDGFR and various integrins. Acting as a bridge between bacterial and eukaryotic glycans, Gal1 promotes invasion, increasing not only the number of infected cells but also the number of inclusions per cell and the number of bacteria per inclusion. Lactose, glycanases or neutralizing antibodies against glycosylated receptors decrease the magnitude of chlamydial infections. In agreement, mice KO for complex N-glycan-forming enzymes and Gal1 are less susceptible to infection. These findings suggest that hijacking bacterial glycan-Gal1-glycosylated receptors bridge could be a new tool to prevent cell invasion and overall Ctr infection. Once inside the cell, Ctr avoids its degradation in the phagocytic pathway by hijacking Rab proteins, the main controllers of intracellular transport. By bacterial-driven mechanisms, certain Rabs are recruited to the chlamydial inclusion while others are excluded. We have described that Ctr intercepts Rab14-mediated transport not only to evade fusion with lysosomes but also to acquire sphingolipids synthesized at the Golgi apparatus. Molecular mechanisms underlying how these bacteria manipulate intracellular transport are a matter of intense study. We demonstrate that Ctr provokes Akt phosphorylation along its entire developmental life cycle and recruits phosphorylated Akt (pAkt) to the inclusion membrane. As a consequence, Akt Substrate of 160 kDa (AS160), also known as TBC1D4, a GTPase Activating Protein (GAP) for Rab14, is phosphorylated and therefore inactivated. Phosphorylated AS160 (pAS160) loses its ability to promote GTP hydrolysis, favoring Rab14 binding to GTP. Akt inhibition by an allosteric isoform-specific Akt inhibitor (iAkt) prevents AS160 phosphorylation and reduces Rab14 recruitment to chlamydial inclusions. iAkt further impairs sphingolipids acquisition by Ctr-inclusion and provokes lipid retention at the Golgi apparatus. Consequently, treatment with iAkt decreases chlamydial inclusion size, bacterial multiplication, and infectivity in a dose-dependent manner. Similar results were found in AS160-depleted cells. By electron microscopy, we observed that iAkt generates abnormal bacterial forms as those reported after sphingolipids deprivation or Rab14 silencing. Taken together, our findings indicate that targeting the Akt/AS160/Rab14 axis could constitute a novel strategy to limit chlamydial infections, mainly for those caused by antibiotic-resistant bacteria.
Fil: Damiani, Maria Elena. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
XXXVII Reunión Científica Anual de la Sociedad de Biología de Cuyo
San Luis
Argentina
Sociedad de Biología de Cuyo
Materia
CHLAMYDIA TRACHOMATIS
ANTI-CHLAMYDIAL AGENTS
PREVENTIVE STRATEGIES
TRERAPEUTICAL STRATEGIES
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/236617

id CONICETDig_92b27a9f026392889e7e866aa4a8c17f
oai_identifier_str oai:ri.conicet.gov.ar:11336/236617
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Sexually-transmitted infections: What´s new about the control of chlamydia trachomatisDamiani, Maria ElenaCHLAMYDIA TRACHOMATISANTI-CHLAMYDIAL AGENTSPREVENTIVE STRATEGIESTRERAPEUTICAL STRATEGIEShttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Chlamydia trachomatis (Ctr) is the most common bacterial cause of sexually transmitted infections (STIs). The World Health Organization (WHO) estimates that 131 million are infected each year, mainly young people of reproductive age. In women, Ctr causes cervicitis, endometritis, salpingitis, which frequently persist along time leading to serious complications such as pelvic inflammatory disease, spontaneous abortions and tubal infertility. Newborns, when infected in the birth canal, can develop conjunctivitis and pneumonia; whereas men can suffer urethritis, prostatitis, and epididymitis. Ctr is the main cause of preventable blindness or trachoma worldwide. There was an epidemiological alert in Argentina in August 2018 for the appearance of venereal lymphogranuloma. The asymptomatic nature of most of the infections makes diagnosis and treatment difficult. Besides, the lack of a preventive vaccine and the antibiotic resistance increase reveal the need for new tools for the prevention and control of chlamydial infections. Ctr invades cervical epithelial cells through numerous receptors, many of them glycosylated, and survives and multiplies intracellularly in a vesicle called inclusion. We have shown the release of a glycan-binding protein, galectin 1 (Gal1), in cervical tissues under inflammation. This lectin engages glycosylated bacterial proteins, like MOMP (Major Outer Membrane Protein) and OmcB, to glycosylated cervical epithelial cell receptors such as PDGFR and various integrins. Acting as a bridge between bacterial and eukaryotic glycans, Gal1 promotes invasion, increasing not only the number of infected cells but also the number of inclusions per cell and the number of bacteria per inclusion. Lactose, glycanases or neutralizing antibodies against glycosylated receptors decrease the magnitude of chlamydial infections. In agreement, mice KO for complex N-glycan-forming enzymes and Gal1 are less susceptible to infection. These findings suggest that hijacking bacterial glycan-Gal1-glycosylated receptors bridge could be a new tool to prevent cell invasion and overall Ctr infection. Once inside the cell, Ctr avoids its degradation in the phagocytic pathway by hijacking Rab proteins, the main controllers of intracellular transport. By bacterial-driven mechanisms, certain Rabs are recruited to the chlamydial inclusion while others are excluded. We have described that Ctr intercepts Rab14-mediated transport not only to evade fusion with lysosomes but also to acquire sphingolipids synthesized at the Golgi apparatus. Molecular mechanisms underlying how these bacteria manipulate intracellular transport are a matter of intense study. We demonstrate that Ctr provokes Akt phosphorylation along its entire developmental life cycle and recruits phosphorylated Akt (pAkt) to the inclusion membrane. As a consequence, Akt Substrate of 160 kDa (AS160), also known as TBC1D4, a GTPase Activating Protein (GAP) for Rab14, is phosphorylated and therefore inactivated. Phosphorylated AS160 (pAS160) loses its ability to promote GTP hydrolysis, favoring Rab14 binding to GTP. Akt inhibition by an allosteric isoform-specific Akt inhibitor (iAkt) prevents AS160 phosphorylation and reduces Rab14 recruitment to chlamydial inclusions. iAkt further impairs sphingolipids acquisition by Ctr-inclusion and provokes lipid retention at the Golgi apparatus. Consequently, treatment with iAkt decreases chlamydial inclusion size, bacterial multiplication, and infectivity in a dose-dependent manner. Similar results were found in AS160-depleted cells. By electron microscopy, we observed that iAkt generates abnormal bacterial forms as those reported after sphingolipids deprivation or Rab14 silencing. Taken together, our findings indicate that targeting the Akt/AS160/Rab14 axis could constitute a novel strategy to limit chlamydial infections, mainly for those caused by antibiotic-resistant bacteria.Fil: Damiani, Maria Elena. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; ArgentinaXXXVII Reunión Científica Anual de la Sociedad de Biología de CuyoSan LuisArgentinaSociedad de Biología de CuyoTech Science PressBurgos, MarioPiezzi, Ramon Salvador2019info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectReuniónJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/236617Sexually-transmitted infections: What´s new about the control of chlamydia trachomatis; XXXVII Reunión Científica Anual de la Sociedad de Biología de Cuyo; San Luis; Argentina; 2019; 8-90327-9545CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://sbcuyo.org.ar/wp-content/uploads/2019/12/Libro-BIOCELL-2019.pdfNacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:13:52Zoai:ri.conicet.gov.ar:11336/236617instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:13:53.237CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Sexually-transmitted infections: What´s new about the control of chlamydia trachomatis
title Sexually-transmitted infections: What´s new about the control of chlamydia trachomatis
spellingShingle Sexually-transmitted infections: What´s new about the control of chlamydia trachomatis
Damiani, Maria Elena
CHLAMYDIA TRACHOMATIS
ANTI-CHLAMYDIAL AGENTS
PREVENTIVE STRATEGIES
TRERAPEUTICAL STRATEGIES
title_short Sexually-transmitted infections: What´s new about the control of chlamydia trachomatis
title_full Sexually-transmitted infections: What´s new about the control of chlamydia trachomatis
title_fullStr Sexually-transmitted infections: What´s new about the control of chlamydia trachomatis
title_full_unstemmed Sexually-transmitted infections: What´s new about the control of chlamydia trachomatis
title_sort Sexually-transmitted infections: What´s new about the control of chlamydia trachomatis
dc.creator.none.fl_str_mv Damiani, Maria Elena
author Damiani, Maria Elena
author_facet Damiani, Maria Elena
author_role author
dc.contributor.none.fl_str_mv Burgos, Mario
Piezzi, Ramon Salvador
dc.subject.none.fl_str_mv CHLAMYDIA TRACHOMATIS
ANTI-CHLAMYDIAL AGENTS
PREVENTIVE STRATEGIES
TRERAPEUTICAL STRATEGIES
topic CHLAMYDIA TRACHOMATIS
ANTI-CHLAMYDIAL AGENTS
PREVENTIVE STRATEGIES
TRERAPEUTICAL STRATEGIES
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Chlamydia trachomatis (Ctr) is the most common bacterial cause of sexually transmitted infections (STIs). The World Health Organization (WHO) estimates that 131 million are infected each year, mainly young people of reproductive age. In women, Ctr causes cervicitis, endometritis, salpingitis, which frequently persist along time leading to serious complications such as pelvic inflammatory disease, spontaneous abortions and tubal infertility. Newborns, when infected in the birth canal, can develop conjunctivitis and pneumonia; whereas men can suffer urethritis, prostatitis, and epididymitis. Ctr is the main cause of preventable blindness or trachoma worldwide. There was an epidemiological alert in Argentina in August 2018 for the appearance of venereal lymphogranuloma. The asymptomatic nature of most of the infections makes diagnosis and treatment difficult. Besides, the lack of a preventive vaccine and the antibiotic resistance increase reveal the need for new tools for the prevention and control of chlamydial infections. Ctr invades cervical epithelial cells through numerous receptors, many of them glycosylated, and survives and multiplies intracellularly in a vesicle called inclusion. We have shown the release of a glycan-binding protein, galectin 1 (Gal1), in cervical tissues under inflammation. This lectin engages glycosylated bacterial proteins, like MOMP (Major Outer Membrane Protein) and OmcB, to glycosylated cervical epithelial cell receptors such as PDGFR and various integrins. Acting as a bridge between bacterial and eukaryotic glycans, Gal1 promotes invasion, increasing not only the number of infected cells but also the number of inclusions per cell and the number of bacteria per inclusion. Lactose, glycanases or neutralizing antibodies against glycosylated receptors decrease the magnitude of chlamydial infections. In agreement, mice KO for complex N-glycan-forming enzymes and Gal1 are less susceptible to infection. These findings suggest that hijacking bacterial glycan-Gal1-glycosylated receptors bridge could be a new tool to prevent cell invasion and overall Ctr infection. Once inside the cell, Ctr avoids its degradation in the phagocytic pathway by hijacking Rab proteins, the main controllers of intracellular transport. By bacterial-driven mechanisms, certain Rabs are recruited to the chlamydial inclusion while others are excluded. We have described that Ctr intercepts Rab14-mediated transport not only to evade fusion with lysosomes but also to acquire sphingolipids synthesized at the Golgi apparatus. Molecular mechanisms underlying how these bacteria manipulate intracellular transport are a matter of intense study. We demonstrate that Ctr provokes Akt phosphorylation along its entire developmental life cycle and recruits phosphorylated Akt (pAkt) to the inclusion membrane. As a consequence, Akt Substrate of 160 kDa (AS160), also known as TBC1D4, a GTPase Activating Protein (GAP) for Rab14, is phosphorylated and therefore inactivated. Phosphorylated AS160 (pAS160) loses its ability to promote GTP hydrolysis, favoring Rab14 binding to GTP. Akt inhibition by an allosteric isoform-specific Akt inhibitor (iAkt) prevents AS160 phosphorylation and reduces Rab14 recruitment to chlamydial inclusions. iAkt further impairs sphingolipids acquisition by Ctr-inclusion and provokes lipid retention at the Golgi apparatus. Consequently, treatment with iAkt decreases chlamydial inclusion size, bacterial multiplication, and infectivity in a dose-dependent manner. Similar results were found in AS160-depleted cells. By electron microscopy, we observed that iAkt generates abnormal bacterial forms as those reported after sphingolipids deprivation or Rab14 silencing. Taken together, our findings indicate that targeting the Akt/AS160/Rab14 axis could constitute a novel strategy to limit chlamydial infections, mainly for those caused by antibiotic-resistant bacteria.
Fil: Damiani, Maria Elena. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina
XXXVII Reunión Científica Anual de la Sociedad de Biología de Cuyo
San Luis
Argentina
Sociedad de Biología de Cuyo
description Chlamydia trachomatis (Ctr) is the most common bacterial cause of sexually transmitted infections (STIs). The World Health Organization (WHO) estimates that 131 million are infected each year, mainly young people of reproductive age. In women, Ctr causes cervicitis, endometritis, salpingitis, which frequently persist along time leading to serious complications such as pelvic inflammatory disease, spontaneous abortions and tubal infertility. Newborns, when infected in the birth canal, can develop conjunctivitis and pneumonia; whereas men can suffer urethritis, prostatitis, and epididymitis. Ctr is the main cause of preventable blindness or trachoma worldwide. There was an epidemiological alert in Argentina in August 2018 for the appearance of venereal lymphogranuloma. The asymptomatic nature of most of the infections makes diagnosis and treatment difficult. Besides, the lack of a preventive vaccine and the antibiotic resistance increase reveal the need for new tools for the prevention and control of chlamydial infections. Ctr invades cervical epithelial cells through numerous receptors, many of them glycosylated, and survives and multiplies intracellularly in a vesicle called inclusion. We have shown the release of a glycan-binding protein, galectin 1 (Gal1), in cervical tissues under inflammation. This lectin engages glycosylated bacterial proteins, like MOMP (Major Outer Membrane Protein) and OmcB, to glycosylated cervical epithelial cell receptors such as PDGFR and various integrins. Acting as a bridge between bacterial and eukaryotic glycans, Gal1 promotes invasion, increasing not only the number of infected cells but also the number of inclusions per cell and the number of bacteria per inclusion. Lactose, glycanases or neutralizing antibodies against glycosylated receptors decrease the magnitude of chlamydial infections. In agreement, mice KO for complex N-glycan-forming enzymes and Gal1 are less susceptible to infection. These findings suggest that hijacking bacterial glycan-Gal1-glycosylated receptors bridge could be a new tool to prevent cell invasion and overall Ctr infection. Once inside the cell, Ctr avoids its degradation in the phagocytic pathway by hijacking Rab proteins, the main controllers of intracellular transport. By bacterial-driven mechanisms, certain Rabs are recruited to the chlamydial inclusion while others are excluded. We have described that Ctr intercepts Rab14-mediated transport not only to evade fusion with lysosomes but also to acquire sphingolipids synthesized at the Golgi apparatus. Molecular mechanisms underlying how these bacteria manipulate intracellular transport are a matter of intense study. We demonstrate that Ctr provokes Akt phosphorylation along its entire developmental life cycle and recruits phosphorylated Akt (pAkt) to the inclusion membrane. As a consequence, Akt Substrate of 160 kDa (AS160), also known as TBC1D4, a GTPase Activating Protein (GAP) for Rab14, is phosphorylated and therefore inactivated. Phosphorylated AS160 (pAS160) loses its ability to promote GTP hydrolysis, favoring Rab14 binding to GTP. Akt inhibition by an allosteric isoform-specific Akt inhibitor (iAkt) prevents AS160 phosphorylation and reduces Rab14 recruitment to chlamydial inclusions. iAkt further impairs sphingolipids acquisition by Ctr-inclusion and provokes lipid retention at the Golgi apparatus. Consequently, treatment with iAkt decreases chlamydial inclusion size, bacterial multiplication, and infectivity in a dose-dependent manner. Similar results were found in AS160-depleted cells. By electron microscopy, we observed that iAkt generates abnormal bacterial forms as those reported after sphingolipids deprivation or Rab14 silencing. Taken together, our findings indicate that targeting the Akt/AS160/Rab14 axis could constitute a novel strategy to limit chlamydial infections, mainly for those caused by antibiotic-resistant bacteria.
publishDate 2019
dc.date.none.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/conferenceObject
Reunión
Journal
http://purl.org/coar/resource_type/c_5794
info:ar-repo/semantics/documentoDeConferencia
status_str publishedVersion
format conferenceObject
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/236617
Sexually-transmitted infections: What´s new about the control of chlamydia trachomatis; XXXVII Reunión Científica Anual de la Sociedad de Biología de Cuyo; San Luis; Argentina; 2019; 8-9
0327-9545
CONICET Digital
CONICET
url http://hdl.handle.net/11336/236617
identifier_str_mv Sexually-transmitted infections: What´s new about the control of chlamydia trachomatis; XXXVII Reunión Científica Anual de la Sociedad de Biología de Cuyo; San Luis; Argentina; 2019; 8-9
0327-9545
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://sbcuyo.org.ar/wp-content/uploads/2019/12/Libro-BIOCELL-2019.pdf
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.coverage.none.fl_str_mv Nacional
dc.publisher.none.fl_str_mv Tech Science Press
publisher.none.fl_str_mv Tech Science Press
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846781552551264256
score 12.982451